Hippocampal pathology in schizophrenia: Magnetic resonance imaging and spectroscopy studies

Psychiatry Research - Neuroimaging

Volumn 98, Issue 3, 2000, Pages 163-175

  Kegeles, Lawrence S ^a,b   Shungu, Dikoma C ^a   Anjilvel, Satish ^a,b   Chan, Stephen ^a   Ellis, Steven P ^a,b   Xanthopoulos, Eric ^a,b   Malaspina, Dolores ^a,c   Gorman, Jack M ^a,c   Mann, J John ^a,b   Laruelle, Marc ^a,b   Kaufmann, Charles A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Dept Neurosci New York Stt P   (United States)

^c NONE   (United States)

Author keywords

Hippocampus; Magnetic resonance imaging; Neurochemistry; Proton magnetic resonance spectroscopy; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; CLOZAPINE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; TEMPORAL LOBE;

ADULT; ASPARTIC ACID; CASE-CONTROL STUDIES; DOMINANCE, CEREBRAL; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; SCHIZOPHRENIA;

EID: 0034657022     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(00)00044-5     Document Type: Article

References (69)

1. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., Neufeld R.W.J. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Archives of General Psychiatry. 54:1997;959-965.
2. Bertolino A., Callicott J.H., Nawroz S., Mattay V.S., Duyn J.H., Tedeschi G., Frank J.A., Weinberger D.R. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology. 18:1998;1-9.
3. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T.W., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. American Journal of Psychiatry. 153:1996;1554-1563.
4. Bickel P.J., Doksum K.A. Mathematical Statistics: Basic Ideas and Selected Topics. 1977;Holden-Day, San Francisco.
5. Bogerts B., Ashtari M., Degreef G., Alvir J.M., Bilder R.M., Lieberman J.A. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Research. 35:1990;1-13.
6. Bogerts B., Meertz E., Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia. Archives of General Psychiatry. 42:1985;784-791.
7. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biological Psychiatry. 36:1994;792-800.
8. Cecil K.M., Lenkinski R.E., Gur R.E., Gur R.C. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology. 20:1999;131-140.
9. Charles H.C., Lazeyras F., Tupler L.A., Krishnan K.R.R. Reproducibility of high spatial resolution proton magnetic resonance spectroscopic imaging in the human brain. Magnetic Resonance in Medicine. 35:1996;606-610.
10. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Academic Radiology. 1:1994;211-216.
11. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Review of Psychiatry. 3:1996;241-253.
12. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. Journal of Neurochemistry. 52:1989;1781-1786.
13. DeLisi L.E., Tew W., Xie S., Hoff A.L., Sakuma M., Kushner M., Lee G., Shedlack K., Smith A.M., Grimson R. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biological Psychiatry. 38:1995;349-360.
14. Ellison Z.R., Wright I.C., McGuire P.K. Neuroimage. 5:1997;S273.
15. Fukuzako H., Takeuchi K., Hokazono Y., Fukuzako T., Yamada K., Hashiguchi T., Obo Y., Ueyama K., Takigawa M., Fujimoto T. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Research: Neuroimaging. 61:1995;193-200.
16. Gattaz W.F., Gasser T., Beckmann H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biological Psychiatry. 20:1985;360-366.
17. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
18. Hetherington H.P., Newcomer B.R., Pan J.W. Measurements of human cerebral GABA at 4T (abstract). Proceedings of the International Society for Magnetic Resonance in Medicine. 1:1997;240.
19. 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magnetic Resonance in Medicine. 36:1996;21-29.
20. Hyde T., Casanova M., Kleinman J.E., Weinberger D.R. Neuroanatomical and neurochemical pathology in schizophrenia. American Psychiatric Press Review in Psychiatry. 10:1991;7-23.
21. Jack C.R. MRI-based hippocampal volume measurements in epilepsy. Epilepsia. 35:1994;S21-S29.
22. Jakob H., Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. Journal of Neural Transmission. 65:1986;303-326.
23. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry. 148:1991;1301-1308.
24. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
25. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 13:1987;261-276.
26. Kegeles L.S., Humaran T.J., Mann J.J. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biological Psychiatry. 44:1998;382-398.
27. Kelsoe J.R. Jr., Cadet J.L., Pickar D., Weinberger D.R. Quantitative neuroanatomy in schizophrenia. A controlled magnetic resonance imaging study. Archives of General Psychiatry. 45:1988;533-541.
28. Keltner J.R., Wald L.L., Christensen J.D., Maas L.C., Moore C.M., Cohen B.M., Renshaw P.F. A technique for detecting GABA in the human brain with PRESS localization and optimized refocusing spectral editing radiofrequency pulses. Magnetic Resonance in Medicine. 36:1996;458-461.
29. Kerwin R.W., Patel S., Meldrum B.S., Czudek C., Reynolds G.P. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet. 1:1988;583-584.
30. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters. 20:1980;379-382.
31. Kirk R.E. Experimental Design: Procedures for the Behavioral Sciences. 1982;Brooks/Cole Publishing Company, Pacific Grove, California.
32. Korpi E.R., Kaufmann C.A., Marnela K.-M., Weinberger D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Research. 20:1987;337-345.
33. Kovelman J.A., Scheibel A.B. A neurohistological correlate of schizophrenia. Biological Psychiatry. 19:1984;1602-1621.
34. Lillrank S.M., Lipska B.K., Weinberger D.R. Neurodevelopmental animal models of schizophrenia. Clinical Neuroscience. 3:1995;98-104.
35. Lim K.O., Spielman D.M. Estimating NAA in cortical gray matter with applications for measuring changes due to aging. Magnetic Resonance in Medicine. 37:1997;372-377.
36. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychological Medicine. 25:1995;1201-1209.
37. Marion D., Ikura M., Bax A. Improved solvent suppression in one- and two-dimensional NMR spectroscopy by convolution of time-domain data. Journal of Magnetic Resonance. 84:1989;425-430.
38. Marquardt D. An algorithm for least-squares estimation of nonlinear parameters. Journal of Applied Mathematics. 11:1963;431-441.
39. Mason G.F., Pan J.W., Ponder S.L., Twieg D.B., Pohost G.M., Hetherington H.P. Detection of brain glutamate and glutamine in spectroscopic images at 4.1 T. Magnetic Resonance in Medicine. 32:1994;142-145.
40. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience. 17:1997;2921-2927.
41. 1H MRS) of the hippocampal formation in schizophrenia: a pilot study. British Journal of Psychiatry. 165:1994;481-485.
42. 1H-NMR-spectroscopy of the limbic temporal lobe in patients with schizophrenia. Nasrallah H.A., Pettegrew J.W. NMR Spectroscopy in Psychiatric Brain Disorders. 1995;1-20 American Psychiatric Press, Inc, Washington, DC.
43. Nelson M.D., Saykin A.J., Flashman L.A., Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Archives of General Psychiatry. 55:1998;433-440.
44. Nurnberger J., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., Severe J.B., Malaspina D., Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Archives of General Psychiatry. 51:1994;849-859.
45. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 9:1971;97-113.
46. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry. 52:1995;998-1007.
47. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychological Reports. 10:1962;799-812.
48. Pearlson G.D., Barta P.E., Powers R.E., Menon R.R., Richards S.S., Aylward E.H., Federman E.B., Chase G.A., Petty R.G., Tien A.Y. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. Biological Psychiatry. 41:1997;1-14.
49. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neuroscience Letters. 28:1982;81-85.
50. Renshaw P.F., Lafer B., Babb S.M., Fava M., Stoll A.L., Christensen J.D., Moore C.M., Yurgelun-Todd D.A., Bonello C.M., Pillay S.S., Rothschild A.J., Nierenberg A.A., Rosenbaum J.F., Cohen B.M. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry. 41:1997;837-843.
51. Renshaw P.F., Yurgelun-Todd D.A., Tohen M., Gruber S., Cohen B.M. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. American Journal of Psychiatry. 152:1995;444-446.
52. 1H NMR spectra of glutamate in the human brain. Magnetic Resonance Medicine. 25:1992;94-106.
53. 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proceedings of the National Academy of Sciences USA. 90:1993;5662-5666.
54. Shenton M.E., Kikinis R., Jolesz F.A., Pollak S.D., LeMay M., Wible C.G., Hokama H., Martin J., Metcalf D., Coleman M. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. New England Journal of Medicine. 327:1992;604-612.
55. 2H NMR spectroscopy using water as an internal intensity reference. Magnetic Resonance in Medicine. 28:1992;105-121.
56. Spitzer, R.L., Williams, J.B.W., Gibbon, N., First, M.D., 1987. Structured Clinical Interview for DSM-III-R (SCID). New York State Psychiatric Institute, Biometrics Research Department, New York.
57. Stanley J.A., Drost D.J., Williamson P.C., Carr T.J. In vivo proton MRS study of glutamate and schizophrenia. Nasrallah H.A., Pettegrew J.W. NMR Spectroscopy in Psychiatric Brain Disorders. 1995;21-44 American Psychiatric Press, Inc, Washington, DC.
58. 1H MR spectra. Magnetic Resonance in Medicine. 34:1995;17-24.
59. Stefanis N., Yakely J., Frangou S., Sharma T., O'Connell P., Morgan K., Murray R. Pregnancy and birth complications (PBC)-associated hippocampal volume reduction in sporadic schizophrenia. Schizophrenia Research. 24:1997;S157.
60. Suddath R.L., Casanova M.F., Goldberg T.E., Daniel D.G., Kelsoe J. Jr., Weinberger D.R. Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. American Journal of Psychiatry. 146:1989;464-472.
61. Suddath R.L., Christison G.W., Torrey E.F., Casanova M.F., Weinberger D.R. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. New England Journal of Medicine. 322:1990;789-794.
62. Swayze V.W.I., Andreasen N.C., Alliger R.J., Yuh W.T., Ehrhardt J.C. Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study [see comments]. Biological Psychiatry. 31:1992;221-240.
63. Torres I.J., Flashman L.A., O'Leary D.S., Swayze II V., Andreasen N.C. Lack of an association between delayed memory and hippocampal and temporal lobe size in patients with schizophrenia and healthy controls. Biological Psychiatry. 42:1997;1087-1096.
64. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archives of General Psychiatry. 52:1995;829-836.
65. Ulas J., Cotman C.W. Excitatory amino acid receptors in schizophrenia. Schizophrenia Bulletin. 19:1993;105-117.
66. Wachtel H., Turski L. Glutamate: a new target in schizophrenia? Trends in Pharmacology. 11:1990;219-220.
67. Wechsler D. WAIS-R Manual. 1981;Psychological Corporation, New York.
68. Yurgelun-Todd D.A., Renshaw P.F., Gruber S.A., Waternaux C., Cohen B.M. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophrenia Research. 19:1996;55-59.
69. Zipursky R.B., Marsh L., Lim K.O., Dement S., Shear P.K., Sullivan E.V., Murphy G.M., Csernansky J.G., Pfefferbaum A. Volumetric MRI assessment of temporal lobe structures in schizophrenia. Biological Psychiatry. 35:1994;501-551.